RGD peptide (Arg-Gly-Asp) Clinical Trials

Size	Price	Qty
10mg	USD 147
1g	USD 2,700

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate RGD peptide derivatives as PET/CT radiotracers for imaging integrin expression and angiogenesis across diverse oncological, cardiovascular, and inflammatory conditions. These studies investigate applications in solid tumors and non-malignant pathologies, with recruitment statuses ranging from active and completed to terminated or withdrawn. Prominent academic, clinical, and industry sponsors include Peking Union Medical College Hospital, Siemens Molecular Imaging, and Radboud University Medical Center.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06693986	RECRUITING	Adenocarcinoma of Pancreas	Masonic Cancer Center, University of Minnesota	2024-12-27	PHASE1
NCT01608516	TERMINATED	Inflammation; Atheromatous Plaques; Carotid Artery Diseases	University of Lausanne Hospitals	2012-04	PHASE1; PHASE2
NCT05549024	RECRUITING	Breast Cancer; Prostate Cancer; Brain Tumor; PET/CT Imaging	Peking Union Medical College Hospital	2022-08-16	EARLY_PHASE1
NCT05543954	UNKNOWN	Lung Neoplasms	Peking Union Medical College Hospital	2022-09-03	EARLY_PHASE1
NCT06632860	RECRUITING	Iodine-resistant Thyroid Cancer; Meningioma; NETs	Peking Union Medical College Hospital	2024-08-01	EARLY_PHASE1
NCT03505346	UNKNOWN	Chronic Ischemic Heart Disease	Rigshospitalet, Denmark	2024-01-01	PHASE2
NCT06068179	RECRUITING	Graves' Disease	The First Affiliated Hospital of Xiamen University	2023-10-16	PHASE2; PHASE3
NCT06936605	NOT_YET_RECRUITING	Intrabony Defect; Periodontal Diseases; Alveolar Bone Loss	Minia University	2025-04-15
NCT07028606	ACTIVE_NOT_RECRUITING	Alveolar Bone Resorption	Al-Azhar University	2024-05-09	PHASE1
NCT04191460	RECRUITING	Squamous Cell Carcinoma of the Head and Neck; Oral Cancer; Squamous Cell Carcinoma of the Oral Cavity	Erasmus Medical Center	2022-07-12	PHASE2
NCT06632873	RECRUITING	SSTR2 and Integrin αVβ3 Positive Tumors	Peking Union Medical College Hospital	2024-09-01	EARLY_PHASE1
NCT06638034	RECRUITING	FAP- Expressing Positive Tumors; RGD- Expressing Positive Tumors	Peking Union Medical College Hospital	2024-05-01	EARLY_PHASE1
NCT05013086	UNKNOWN	Integrin αVβ3 Positive Tumors	Peking Union Medical College Hospital	2021-10-01	EARLY_PHASE1
NCT07660406	RECRUITING	Keloid	Peking Union Medical College Hospital	2024-08-01	PHASE1; PHASE2
NCT06585852	RECRUITING	Implant Dentistry	Al-Azhar University	2023-08-01
NCT05515783	UNKNOWN	Tumor	First Affiliated Hospital of Fujian Medical University	2022-05-01	PHASE1; PHASE2
NCT04871217	UNKNOWN	Coronary Artery Disease	Turku University Hospital	2018-12-04
NCT03809689	TERMINATED	Myocardial Infarction, Acute; Myocardial Reperfusion; Chronic Ischemic Heart Disease	University of Lausanne Hospitals	2018-11-01
NCT02666547	TERMINATED	Pathological Angiogenesis	University of Lausanne Hospitals	2014-03	PHASE1
NCT05968118	UNKNOWN	Peripheral Artery Disease	Beijing Northland Biotech. Co., Ltd.	2022-07-29	PHASE3
NCT05543317	COMPLETED	Tumor, Solid; Positron-Emission Tomography	The First Affiliated Hospital of Xiamen University	2022-07-01
NCT04222543	UNKNOWN	Oropharyngeal Squamous Cell Carcinoma	Radboud University Medical Center	2019-11-22	PHASE2
NCT05653245	COMPLETED	Periodontitis	Minia University	2021-03-15	PHASE1; PHASE2
NCT03655977	UNKNOWN	Cervical Cancer	Rigshospitalet, Denmark	2018-09-01
NCT03393689	UNKNOWN	Acoustic Neuroma	Rigshospitalet, Denmark	2018-01-02	PHASE2
NCT02817945	UNKNOWN	Lung Cancer; Neuroendocrine Neoplasm	Peking Union Medical College Hospital	2016-06-01	EARLY_PHASE1
NCT02995642	WITHDRAWN	Aortic Aneurysm, Abdominal; Carotid Atherosclerosis	Stanford University	2019-10	PHASE2
NCT03445884	COMPLETED	Acute Myocardial Infarction	Rigshospitalet, Denmark	2018-02-20	PHASE2
NCT02317393	COMPLETED	Non-seminomatous Germ Cell Tumors; Metastasis	Centre Francois Baclesse	2014-12	PHASE2
NCT03364270	COMPLETED	Carotid Arteries	Balaji Tamarappoo	2018-10-10	PHASE2
NCT03974685	COMPLETED	Healthy	RDO Pharm.	2018-12-12	PHASE1
NCT02490891	COMPLETED	Lymphoma	Centre Henri Becquerel	2015-11-13	PHASE2
NCT02325349	TERMINATED	Advanced Head and Neck Carcinoma; Advanced Non-small Cell Lung Carcinoma	Assistance Publique - Hôpitaux de Paris	2015-03-20	PHASE2
NCT02749019	UNKNOWN	Breast Cancer	Peking Union Medical College Hospital	2015-07	PHASE1
NCT03384511	COMPLETED	Malignancies; Stomach Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Breast Cancer; Ovary Cancer; Cervical Cancer	Shandong Cancer Hospital and Institute	2016-09-30	PHASE4
NCT02747290	UNKNOWN	Prostate Cancer	Peking Union Medical College Hospital	2014-07	EARLY_PHASE1
NCT01806675	COMPLETED	Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Male Breast Cancer; Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Adult Brain Tumor; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Colon Cancer; Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity; Recurrent Hypopharyngeal Cancer; Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity; Recurrent Laryngeal Cancer; Recurrent Lip and Oral Cavity Cancer; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Nasopharyngeal Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Oropharyngeal Cancer; Recurrent Pancreatic Cancer; Recurrent Paranasal Sinus and Nasal Cavity Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Salivary Gland Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Renal Cell Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVA Salivary Gland Cancer; Stage IVB Colon Cancer; Stage IVB Salivary Gland Cancer; Stage IVC Salivary Gland Cancer; Tongue Cancer; Unspecified Adult Solid Tumor, Protocol Specific	Sanjiv Sam Gambhir	2013-03-04	PHASE1; PHASE2
NCT01968226	TERMINATED	Carotid Artery Disease; Carotid Stenosis	The Cleveland Clinic	2013-11	PHASE2
NCT01956734	COMPLETED	Glioblastoma Multiforme; Recurrent Tumor	Clinica Universidad de Navarra, Universidad de Navarra	2013-09	PHASE1
NCT01492192	TERMINATED	Carcinoma, Renal Cell	Oxford University Hospitals NHS Trust	2013-05	PHASE2
NCT00805376	COMPLETED	Brain Cancer; Central Nervous System Diseases	DNAtrix, Inc.	2009-02	PHASE1
NCT01582516	COMPLETED	Brain Tumor; Recurring Glioblastoma	Erasmus Medical Center	2010-06	PHASE1; PHASE2
NCT02481726	COMPLETED	Lung Cancer; Lung Tuberculosis	Xijing Hospital	2014-03	PHASE1; PHASE2
NCT01602471	TERMINATED	Carotid Stenosis	Siemens Molecular Imaging	2012-05	PHASE2
NCT00988936	COMPLETED	Metastatic Breast Cancer; Metastatic Colon/Rectum Cancer; Non-squamous Non-small Cell Lung Cancer	Siemens Molecular Imaging	2009-09	PHASE2
NCT00562003	COMPLETED	Ovarian Cancer; Primary Peritoneal Cancer	University of Alabama at Birmingham	2007-06	PHASE1
NCT00743353	COMPLETED	Sarcoma; Melanoma; Lung Cancer; Breast Cancer; High Grade Gliomas	Siemens Molecular Imaging	2008-08	EARLY_PHASE1

(data from https://clinicaltrials.gov, updated on 2026-01-07)

Check the RGD peptide (Arg-Gly-Asp) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

RGD peptide binds specifically to cell-surface integrins, such as alpha-v beta-3, thereby disrupting integrin-mediated extracellular matrix adhesion, focal adhesion kinase signaling, and endothelial cell migration. Inhibition of integrin interaction suppresses tumor angiogenesis and cell invasion, providing the functional basis for utilizing radiolabeled RGD constructs in PET/CT molecular imaging of angiogenesis and integrin overexpression across solid tumors and vascular lesions in clinical trials.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).